Background The use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccine (CoronaVac) against SARS-CoV-2 is implemented worldwide. However, …

The coronavirus disease 2019 (COVID-19) pandemic has become a severe healthcare
problem worldwide since the first outbreak in late December 2019. Currently, the COVID-19 …

In June 2021, Thailand was hit by the delta variant of SARS-CoV-2 resulting in the biggest
wave of COVID-19. Due to the widespread delta variant, more than 600 healthcare workers …

A novel infectious respiratory disease was recognized in Wuhan (Hubei Province, China) in
December 2019. In February 2020, the disease was named “coronavirus disease 2019” (…

This study monitored the long-term immune response to severe acute respiratory syndrome
coronavirus (SARS-CoV)-2 infection in patients who had recovered from coronavirus …

The coronavirus 2019 omicron variant has surged rapidly and raises concerns about immune
evasion even in individuals with complete vaccination, because it harbors mutations. Here …

Coronavirus disease 2019 (COVID-19) booster vaccination is being comprehensively
evaluated globally due to waning immunity and the emergence of new severe acute respiratory …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
and the waning of immunity in vaccinated individuals is resulting in increased numbers of …

Seroprevalence studies on SARS-CoV-2 are essential for estimating actual prevalence rates
of infection and vaccination in communities. This study evaluated infection rates based on …

Objectives To report the safety and immunogenicity profile of a protein subunit vaccine (Covovax
TM ) given as a third (booster) dose to individuals primed with different primary vaccine …